Since previous reports demonstrated oncogenic roles of HDAC5 in various cancers such as breast, liver, colon, and lung cancer [13], we hypothesized that inhibition of HDAC5 induction might affect the cellular tolerance to osimertinib. This evidence concerns the gene HDAC5 and lung carcinoma.